2. Academic Validation
  3. Discovery of BI 99179, a potent and selective inhibitor of type I fatty acid synthase with central exposure

Discovery of BI 99179, a potent and selective inhibitor of type I fatty acid synthase with central exposure

  • Bioorg Med Chem Lett. 2011 Oct 1;21(19):5924-7. doi: 10.1016/j.bmcl.2011.07.083.
Jörg T Kley 1,  Jürgen Mack,  Bradford Hamilton,  Stefan Scheuerer,  Norbert Redemann
Affiliations

Affiliation

  • 1 Medicinal Chemistry, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Strasse 65, D-88397 Biberach, Germany. joerg.kley@boehringer-ingelheim.com,
PMID: 21873051 DOI: 10.1016/j.bmcl.2011.07.083
Abstract

Based on a high-throughput screen, cyclopentanecarboxanilides were identified as a new chemotype of non-covalent inhibitors of type I fatty acid synthase (FAS). Starting from initial hits we aimed at generating a tool compound suitable for the in vivo validation of FAS as a therapeutic target. Optimisation yielded BI 99179 which is characterised by high potency, remarkably high selectivity and significant exposure (both peripheral and central) upon oral administration in rats.

Figures
Products